SGMO News and Press, Sangamo Therapeutics Inc. From 03/17/23

2023-03-17 16:16:22 ET Summary Here's a long list of biopharmas exposed to SVB Financial Group. Many of these deposits will be uninsured. However, since SVB Financial Group was quite solvent otherwise, much of these deposits should be recoverable by these small companies. ...

2023-03-10 21:26:19 ET Several smaller pharma and biotech companies have come out and said they have exposure to FDIC-shuttered Silicon Valley Bank ( SIVB ). The biotech was the biggest exposure disclosed so far is Sangamo Therapeutics ( NASDAQ: SGMO ), with $34.4M in ...

Sangamo Therapeutics ( NASDAQ: SGMO ) has determined it will not move forward with a public offering of securities it was considering. The biotech said in an SEC filing it made the determination "after evaluating market conditions as well as ongoing business development discussion...

Sangamo Therapeutics ( NASDAQ: SGMO ) added ~11% on Monday after Wedbush Securities upgraded the genomic medicine company to Outperform from Neutral, noting a recent data readout for the company's Fabry disease candidate ST-920. Announcing updated data from its Phase 1/2 STAAR cli...

Sangamo Therapeutics ( NASDAQ: SGMO ) is up ~5% in after-hours trading Thursday after posting Q4 2022 financial results Wednesday that beat on the top and bottom lines. However, the company's net loss in the quarter widened ~39% to ~$52M (-$0.32 EPS vs -$0.26 EPS). Total opera...

If you’re looking for penny stocks to buy, you might want to get a second opinion. You could go to places like Fintwit or Reddit to discover what the mom-and-pop investors are speculating on. Another way to see varying perceptions of companies is to find out what analysts think. Using ...

Sangamo Therapeutics, Inc. (SGMO) Q4 2022 Results Conference Call February 22, 2023 04:30 PM ET Company Participants Louise Wilkie - VP of IR and Corporate Communications Sandy Macrae - Chief Executive Officer Mark McClung - Chief Operating Officer Prathyusha Durai...

Sangamo Therapeutics press release ( NASDAQ: SGMO ): Q4 GAAP EPS of -$0.32 beats by $0.04 . Revenue of $27.23M (-2.8% Y/Y) beats by $0.37M . For further details see: Sangamo Therapeutics GAAP EPS of -$0.32 beats by $0.04, revenue of $27.23M beats by $0.37M

Conference Call and Webcast Scheduled for 4:30 p.m. Eastern Time Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and fourth quarter and full year 2022 financial results. “2022 was a year of important clinical a...

- Sustained, elevated expression of alpha-galactosidase A (α-Gal A) activity observed in 13 patients for over two years for the longest treated patient as of cutoff date. - Achieved 78% globotriaosylceramide (Gb3) substrate clearance at 6-months and 77% reduction in urine...